Aspirin and salicylic acid decrease c-Myc expression in cancer cells: a potential role in chemoprevention

Tumor Biology

Volumn 37, Issue 2, 2016, Pages 1727-1738

  Ai, Guoqiang ^a   Dachineni, Rakesh ^a   Muley, Pratik ^a   Tummala, Hemachand ^a   Bhat, G Jayarama ^a  

^a SOUTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

Aspirin; c Myc; Colon cancer; Proteasome; Salicylic acid

Indexed keywords

ACETYLSALICYLIC ACID; MESSENGER RNA; MYC PROTEIN; SALICYLIC ACID; MYC PROTEIN, HUMAN; NONSTEROID ANTIINFLAMMATORY AGENT; SALICYLIC ACID DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER PREVENTION; CELL LEVEL; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; GROWTH RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; BIOSYNTHESIS; CELL PROLIFERATION; DRUG EFFECTS; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; GENE EXPRESSION REGULATION; NEOPLASMS; NORTHERN BLOTTING; PATHOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOPREVENTION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOWN-REGULATION; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; SALICYLATES;

EID: 84940061693     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3959-0     Document Type: Article

References (40)

1. Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nature Rev Clin Oncol. 2012;9:259–67.
2. Rothwell PM, Price JF, Fowkes FGR, Zanchetti A, Roncaglioni MC, Tognoni G, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012;379:1602–12.
3. Sahasrabuddhe VV, Gunja MZ, Graubard BI, Trabert B, Schwartz LM, Park Y, et al. Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma. J Natl Cancer Inst. 2012;104:1808–14.
4. Gamba CA, Swetter SM, Stefanick ML, Kubo J, Desai M, Spaunhurst KM, et al. Aspirin is associated with lower melanoma risk among postmenopausal Caucasian women: The Women's Health Initiative. Cancer. 2013;119:1562–9.
5. Veitonmaki T, Tammela TL, Auvinen A, Murtola TJ. Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level. Eur J Cancer. 2013;49:938–45.
6. Luciani MG, Campregher C, Gasche C. Aspirin blocks proliferation in colon cells by inducing a G1 arrest and apoptosis through activation of the checkpoint kinase ATM. Carcinogenesis. 2007;28:2207–17.
7. Qiao L, Hanif R, Sphicas E, Shiff SJ, Rigas B. Effect of aspirin on induction of apoptosis in ht-29 human colon adenocarcinoma cells. Biochem Pharmacol. 1998;55:53–64.
8. Shiff SJ, Koutsos MI, Qiao L, Rigas B. Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. Exp Cell Res. 1996;222:179–88.
9. Goel A, Chang DK, Ricciardiello L, Gasche C, Boland CR. A novel mechanism for aspirin-mediated growth inhibition of human colon cancer cells. Clin Cancer Res. 2003;9:383–90.
10. Pathi S, Jutooru I, Chadalapaka G, Nair V, Lee SO, Safe S. Aspirin inhibits colon cancer cell and tumor growth and downregulates specificity protein (sp) transcription factors. PLoS One. 2012;7:e48208.
11. Bousserouel S, Gosse F, Bouhadjar M, Soler L, Marescaux J, Raul F. Long-term administration of aspirin inhibits tumour formation and triggers anti-neoplastic molecular changes in a pre-clinical model of colon carcinogenesis. Oncol Rep. 2010;23:511–7.
12. Shpitz B, Klein E, Buklan G, Neufeld D, Nissan A, Freund HR, et al. Suppressive effect of aspirin on aberrant crypt foci in patients with colorectal cancer. Gut. 2003;52:1598–601.
13. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA: J Am Med Assoc. 2009;302:649–58.
14. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science. 1994;265:956–9.
15. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res. 2003;110:255–8.
16. Dovizio M, Bruno A, Tacconelli S, Patrignani P: Mode of action of aspirin as a chemopreventive agent. Recent results in cancer research Fortschritte der Krebsforschung Progres dans les recherches sur le cancer 2013;191:39–65
17. Alfonso L, Ai G, Spitale RC, Bhat GJ. Molecular targets of aspirin and cancer prevention. Br J Cancer. 2014;111:61–7.
18. Roberts MS, Rumble RH, Wanwimolruk S, Thomas D, Brooks PM. Pharmacokinetics of aspirin and salicylate in elderly subjects and in patients with alcoholic liver disease. Eur J Clin Pharmacol. 1983;25:253–61.
19. Borthwick GM, Johnson AS, Partington M, Burn J, Wilson R, Arthur HM. Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a cox-independent mechanism. FASEB J. 2006;20:2009–16.
20. Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F. The c-Myc target gene network. Semin Cancer Biol. 2006;16:253–64.
21. Vita M, Henriksson M. The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol. 2006;16:318–30.
22. Amati B. Myc degradation: dancing with ubiquitin ligases. Proc Natl Acad Sci U S A. 2004;101:8843–4.
23. McKeown MR, Bradner JE. Therapeutic strategies to inhibit MYC. Cold Spring Harbor Perspect Med. 2014;4:a014266.
24. Chio II, Yordanov G, Tuveson D. MAX-ing out MYC: a novel small molecule inhibitor against MYC-dependent tumors. J Natl Cancer Inst. 2014;106.
25. Rahl PB, Lin CY, Seila AC, Flynn RA, McCuine S, Burge CB, et al. c-Myc regulates transcriptional pause release. Cell. 2010;141:432–45.
26. Schneider CA, Rasband WS, Eliceiri KW. NIH image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671–5.
27. Alfonso LF, Srivenugopal KS, Arumugam TV, Abbruscato TJ, Weidanz JA, Bhat GJ. Aspirin inhibits camptothecin-induced p21CIP1 levels and potentiates apoptosis in human breast cancer cells. Int J Oncol. 2009;34:597–608.
28. Bae SK, Seo KA, Jung EJ, Kim HS, Yeo CW, Shon JH, et al. Determination of acetylsalicylic acid and its major metabolite, salicylic acid, in human plasma using liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study of Astrix in Korean healthy volunteers. Biomed Chromatogr: BMC. 2008;22:590–5.
29. Conacci-Sorrell M, Ngouenet C, Eisenman RN. Myc-nick: a cytoplasmic cleavage product of Myc that promotes alpha-tubulin acetylation and cell differentiation. Cell. 2010;142:480–93.
30. Din FV, Valanciute A, Houde VP, Zibrova D, Green KA, Sakamoto K, et al. Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. Gastroenterology. 2012;142:1504–15. e1503.
31. Law BK, Waltner-Law ME, Entingh AJ, Chytil A, Aakre ME, Norgaard P, et al. Salicylate-induced growth arrest is associated with inhibition of p70s6k and down-regulation of c-myc, cyclin D1, cyclin a, and proliferating cell nuclear antigen. J Biol Chem. 2000;275:38261–7.
32. Tansey WP. Mammalian MYC proteins and cancer. New J Sci. 2014;2014:1–27.
33. Gregory MA, Hann SR. c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells. Mol Cell Biol. 2000;20:2423–35.
34. Krystal G, Birrer M, Way J, Nau M, Sausville E, Thompson C, et al. Multiple mechanisms for transcriptional regulation of the myc gene family in small-cell lung cancer. Mol Cell Biol. 1988;8:3373–81.
35. Marimuthu S, Chivukula RS, Alfonso LF, Moridani M, Hagen FK, Bhat GJ. Aspirin acetylates multiple cellular proteins in HCT-116 colon cancer cells: identification of novel targets. Int J Oncol. 2011;39:1273–83.
36. Farrell AS, Sears RC. Myc degradation. Cold Spring Harbor Perspect Med. 2014;4:a014365.
37. Forgue-Lafitte M-E, Coudray A-M, Bréant B, Mešter J. Proliferation of the human colon carcinoma cell line HT29: autocrine growth and deregulated expression of the c-myc oncogene. Cancer Res. 1989;49:6566–71.
38. Xu J, Chen Y, Olopade OI. Myc and breast cancer. Genes Cancer. 2010;1:629–40.
39. Toyoshima M, Howie HL, Imakura M, Walsh RM, Annis JE, Chang AN, et al. Functional genomics identifies therapeutic targets for MYC-driven cancer. Proc Natl Acad Sci U S A. 2012;109:9545–50.
40. Fletcher S, Prochownik EV. Small-molecule inhibitors of the Myc oncoprotein. Biochim Biophys Acta. 1849;2015:525–43.